LoQus23 Therapeutics选择LQT-23，一种首创的口服药物，用于亨廷顿舞蹈症临床试验。 LoQus23 Therapeutics selects LQT-23, a first-in-class oral drug, for Huntington’s disease clinical trials.

LoQus23治疗学选择LQT-23为Huntington疾病第一等口服药物候选者, LoQus23 Therapeutics has selected LQT-23 as its first-in-class oral drug candidate for Huntington’s Disease, marking a potential advancement in treatment options for the inherited neurodegenerative disorder. 该化合物旨在针对基本疾病机制,提供新的治疗方法。 The compound is designed to target the underlying disease mechanism, offering a novel therapeutic approach. 该公司计划将LQT-23推进临床试验,以评价其对病人的安全性和有效性。 The company plans to advance LQT-23 into clinical trials to evaluate its safety and efficacy in patients.